VenatoRx Pharmaceuticals, which focuses on discovery and development of novel therapies for highly drug resistant bacterial infections, has been awarded up to $9.4m from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator).
VenatoRx Pharmaceuticals has raised $42m in a Series B funding round led by Versant Ventures and joined by Abingworth and Foresite Capital.
Eli Lilly and Company and Nektar Therapeutics have agreed to jointly develop NKTR-358, a novel immunological therapy discovered by the latter.
A new study has found that artificial intelligence (AI) and machine learning algorithms helped predict instances of schizophrenia with 74% accuracy.
The UK’s Department of Health has announced that 33 research units and groups will get over £120m funding for global health research.
Erytech Pharma and the Queen’s University in Canada have entered into a research collaboration to advance the preclinical development of the former’s eryminase program specifically for the treatment of arginase-1 deficiency.
Daiichi Sankyo, Max Planck Innovation and the Lead Discovery Center have inked an agreement offering Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for cancer treatment to be discovered and developed at the Lead Discovery Center.
The Broad Institute of MIT and Harvard has joined discussions to form a non-exclusive CRISPR-Cas9 joint licensing pool coordinated by MPEG LA, an organization that operates patent pool licensing programs in various institutions and countries.
Shield Therapeutics and Ewopharma have entered into an exclusive sale, supply, distribution and marketing agreement for Feraccru in Switzerland.
Celgene has agreed to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317 for the treatment of solid tumor cancers.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.